NASDAQ
5.50USD
-0.67 (-10.80%)
No scored catalysts in the window yet.
Market cap
121M
P/E
—
EPS
—
Beta
1.20
52W range
4.88-20.3
Day range
5.02–6.00
Open
5.55
Prev close
6.17
Volume
24.6K
Avg volume
7.5K
Dividend
0.00
IPO
2020-09-04
https://www.newsfilecorp.com/release/305422/Graycliff-Closes-First-Tranche-of-LIFE-Financing · 7/16/2026+0.60
https://seekingalpha.com/article/4919830-gdlc-a-high-fee-aggregator-in-a-low-cost-crypto-world · 7/4/2026-0.70
https://www.newsfilecorp.com/release/300374/Graycliff-Exploration-to-Expand-Sudbury-Footprint-Through-the-Acquisition-of-Thirteen-Strategic-Mineral-Claims-Adjacent-to-HighGrade-Shakespeare-Project · 6/5/2026+0.80
https://www.newsfilecorp.com/release/295533/Graycliff-Exploration-Announces-New-CFO-and-Independent-Director · 5/1/2026+0.30
https://www.newsfilecorp.com/release/286521/Graycliff-Exploration-Announces-Private-Placement · 3/6/2026+0.40
https://www.etftrends.com/etf-prime/etf-prime-five-flow-trends-emerge-in-2026/ · 2/4/2026-0.40
https://seekingalpha.com/article/4850862-ethers-out-of-favor-why-im-buying-eth-again-anyway · 12/6/2025+0.80
https://www.newsfilecorp.com/release/276072/Graycliff-Exploration-Update-re-Proposed-Consolidation · 11/26/2025+0.00
https://deadline.com/2025/08/tegna-nexstar-acquisition-talks-fcc-local-tv-1236483684/ · 8/11/2025+0.40
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
